These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 32404526)

  • 1. Therapeutic Efficacy and Resistance Selection of a Lipopeptide Fusion Inhibitor in Simian Immunodeficiency Virus-Infected Rhesus Macaques.
    Yu D; Xue J; Wei H; Cong Z; Chen T; Zhu Y; Chong H; Wei Q; Qin C; He Y
    J Virol; 2020 Jul; 94(15):. PubMed ID: 32404526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Lipopeptide HIV-1/2 Fusion Inhibitor with Highly Potent
    Chong H; Xue J; Xiong S; Cong Z; Ding X; Zhu Y; Liu Z; Chen T; Feng Y; He L; Guo Y; Wei Q; Zhou Y; Qin C; He Y
    J Virol; 2017 Jun; 91(11):. PubMed ID: 28356533
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design of Novel HIV-1/2 Fusion Inhibitors with High Therapeutic Efficacy in Rhesus Monkey Models.
    Chong H; Xue J; Zhu Y; Cong Z; Chen T; Guo Y; Wei Q; Zhou Y; Qin C; He Y
    J Virol; 2018 Aug; 92(16):. PubMed ID: 29899103
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.
    Chong H; Zhu Y; Yu D; He Y
    J Virol; 2018 Oct; 92(20):. PubMed ID: 30089693
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design and Characterization of Cholesterylated Peptide HIV-1/2 Fusion Inhibitors with Extremely Potent and Long-Lasting Antiviral Activity.
    Zhu Y; Chong H; Yu D; Guo Y; Zhou Y; He Y
    J Virol; 2019 Jun; 93(11):. PubMed ID: 30867304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enfuvirtide (T20)-Based Lipopeptide Is a Potent HIV-1 Cell Fusion Inhibitor: Implications for Viral Entry and Inhibition.
    Ding X; Zhang X; Chong H; Zhu Y; Wei H; Wu X; He J; Wang X; He Y
    J Virol; 2017 Sep; 91(18):. PubMed ID: 28659478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exceptional potency and structural basis of a T1249-derived lipopeptide fusion inhibitor against HIV-1, HIV-2, and simian immunodeficiency virus.
    Zhu Y; Zhang X; Ding X; Chong H; Cui S; He J; Wang X; He Y
    J Biol Chem; 2018 Apr; 293(14):5323-5334. PubMed ID: 29425101
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Helical Short-Peptide Fusion Inhibitor with Highly Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.
    Xiong S; Borrego P; Ding X; Zhu Y; Martins A; Chong H; Taveira N; He Y
    J Virol; 2017 Jan; 91(1):. PubMed ID: 27795437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monotherapy with a low-dose lipopeptide HIV fusion inhibitor maintains long-term viral suppression in rhesus macaques.
    Chong H; Xue J; Zhu Y; Cong Z; Chen T; Wei Q; Qin C; He Y
    PLoS Pathog; 2019 Feb; 15(2):e1007552. PubMed ID: 30716118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficient treatment and pre-exposure prophylaxis in rhesus macaques by an HIV fusion-inhibitory lipopeptide.
    Xue J; Chong H; Zhu Y; Zhang J; Tong L; Lu J; Chen T; Cong Z; Wei Q; He Y
    Cell; 2022 Jan; 185(1):131-144.e18. PubMed ID: 34919814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pan-coronavirus fusion inhibitors possess potent inhibitory activity against HIV-1, HIV-2, and simian immunodeficiency virus.
    Yu D; Zhu Y; Yan H; Wu T; Chong H; He Y
    Emerg Microbes Infect; 2021 Dec; 10(1):810-821. PubMed ID: 33847245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Membrane-Anchored Short-Peptide Fusion Inhibitor Fully Protects Target Cells from Infections of Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.
    Tang X; Jin H; Chen Y; Li L; Zhu Y; Chong H; He Y
    J Virol; 2019 Nov; 93(22):. PubMed ID: 31462566
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic Pathway of HIV-1 Resistance to Novel Fusion Inhibitors Targeting the Gp41 Pocket.
    Su Y; Chong H; Xiong S; Qiao Y; Qiu Z; He Y
    J Virol; 2015 Dec; 89(24):12467-79. PubMed ID: 26446597
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Creating an Artificial Tail Anchor as a Novel Strategy To Enhance the Potency of Peptide-Based HIV Fusion Inhibitors.
    Su S; Zhu Y; Ye S; Qi Q; Xia S; Ma Z; Yu F; Wang Q; Zhang R; Jiang S; Lu L
    J Virol; 2017 Jan; 91(1):. PubMed ID: 27795416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In Vitro Selection and Characterization of HIV-1 Variants with Increased Resistance to LP-40, Enfuvirtide-Based Lipopeptide Inhibitor.
    Hu Y; Yu W; Geng X; Zhu Y; Chong H; He Y
    Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35743078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conserved Residue Asn-145 in the C-Terminal Heptad Repeat Region of HIV-1 gp41 is Critical for Viral Fusion and Regulates the Antiviral Activity of Fusion Inhibitors.
    Geng X; Liu Z; Yu D; Qin B; Zhu Y; Cui S; Chong H; He Y
    Viruses; 2019 Jul; 11(7):. PubMed ID: 31277353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Tryptophan-Rich Motif of HIV-1 gp41 Can Interact with the N-Terminal Deep Pocket Site: New Insights into the Structure and Function of gp41 and Its Inhibitors.
    Zhu Y; Ding X; Yu D; Chong H; He Y
    J Virol; 2019 Dec; 94(1):. PubMed ID: 31619552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polyethylene Glycol 40-Modified Peptide with High Therapeutic Efficacy in Simian-Human Immunodeficiency Virus-Acutely Infected Rhesus Monkeys.
    Li M; Cheng S; Ding Y; Wang C; Feng Y; Wang W; Ma L; Li X
    J Virol; 2020 Jul; 94(14):. PubMed ID: 32404523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dolutegravir Monotherapy of Simian Immunodeficiency Virus-Infected Macaques Selects for Several Patterns of Resistance Mutations with Variable Virological Outcomes.
    Van Rompay KKA; Hassounah S; Keele BF; Lifson JD; Ardeshir A; Watanabe J; Pham HT; Chertova E; Sowder R; Balzarini J; Mesplède T; Wainberg MA
    J Virol; 2019 Jan; 93(2):. PubMed ID: 30381490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protocol for evaluating CD8
    Sun Y; Zhang J; Tong L; Lu J; Chen T; Wei Q; He Y; Cong Z; Xue J
    STAR Protoc; 2022 Sep; 3(3):101479. PubMed ID: 35776642
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.